These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

761 related items for PubMed ID: 16537453

  • 1. Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population.
    Simchoni S, Friedman E, Kaufman B, Gershoni-Baruch R, Orr-Urtreger A, Kedar-Barnes I, Shiri-Sverdlov R, Dagan E, Tsabari S, Shohat M, Catane R, King MC, Lahad A, Levy-Lahad E.
    Proc Natl Acad Sci U S A; 2006 Mar 07; 103(10):3770-4. PubMed ID: 16537453
    [Abstract] [Full Text] [Related]

  • 2. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K.
    Clin Cancer Res; 2002 Dec 07; 8(12):3776-81. PubMed ID: 12473589
    [Abstract] [Full Text] [Related]

  • 3. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM, Offit K, Foulkes W, Robson ME, Wacholder S, Eng CM, Karp SE, Begg CB.
    Cancer Epidemiol Biomarkers Prev; 2001 May 07; 10(5):467-73. PubMed ID: 11352856
    [Abstract] [Full Text] [Related]

  • 4. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.
    Milne RL, Osorio A, Ramón y Cajal T, Baiget M, Lasa A, Diaz-Rubio E, de la Hoya M, Caldés T, Teulé A, Lázaro C, Blanco I, Balmaña J, Sánchez-Ollé G, Vega A, Blanco A, Chirivella I, Esteban Cardeñosa E, Durán M, Velasco E, Martínez de Dueñas E, Tejada MI, Miramar MD, Calvo MT, Guillén-Ponce C, Salazar R, San Román C, Urioste M, Benítez J.
    Breast Cancer Res Treat; 2010 Jan 07; 119(1):221-32. PubMed ID: 19370414
    [Abstract] [Full Text] [Related]

  • 5. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
    King MC, Marks JH, Mandell JB, New York Breast Cancer Study Group.
    Science; 2003 Oct 24; 302(5645):643-6. PubMed ID: 14576434
    [Abstract] [Full Text] [Related]

  • 6. Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development.
    Koren-Michowitz M, Friedman E, Gershoni-Baruch R, Brok-Simoni F, Patael Y, Rechavi G, Amariglio N.
    Am J Hematol; 2005 Mar 24; 78(3):203-6. PubMed ID: 15726604
    [Abstract] [Full Text] [Related]

  • 7. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F, Duffy DL, Kay GF, Kedda MA, Spurdle AB, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Australian Ovarian Cancer Study Management Group.
    J Natl Cancer Inst; 2008 Nov 05; 100(21):1519-29. PubMed ID: 18957670
    [Abstract] [Full Text] [Related]

  • 8. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.
    Roa BB, Boyd AA, Volcik K, Richards CS.
    Nat Genet; 1996 Oct 05; 14(2):185-7. PubMed ID: 8841191
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
    Milne RL, Osorio A, Cajal TR, Vega A, Llort G, de la Hoya M, Díez O, Alonso MC, Lazaro C, Blanco I, Sánchez-de-Abajo A, Caldés T, Blanco A, Graña B, Durán M, Velasco E, Chirivella I, Cardeñosa EE, Tejada MI, Beristain E, Miramar MD, Calvo MT, Martínez E, Guillén C, Salazar R, San Román C, Antoniou AC, Urioste M, Benítez J.
    Clin Cancer Res; 2008 May 01; 14(9):2861-9. PubMed ID: 18451254
    [Abstract] [Full Text] [Related]

  • 14. Single-nucleotide polymorphisms in the p53 pathway genes modify cancer risk in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
    Yarden RI, Friedman E, Metsuyanim S, Olender T, Ben-Asher E, Papa MZ.
    Mol Carcinog; 2010 Jun 01; 49(6):545-55. PubMed ID: 20306497
    [Abstract] [Full Text] [Related]

  • 15. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%.
    Oddoux C, Struewing JP, Clayton CM, Neuhausen S, Brody LC, Kaback M, Haas B, Norton L, Borgen P, Jhanwar S, Goldgar D, Ostrer H, Offit K.
    Nat Genet; 1996 Oct 01; 14(2):188-90. PubMed ID: 8841192
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark.
    Soegaard M, Kjaer SK, Cox M, Wozniak E, Høgdall E, Høgdall C, Blaakaer J, Jacobs IJ, Gayther SA, Ramus SJ.
    Clin Cancer Res; 2008 Jun 15; 14(12):3761-7. PubMed ID: 18559594
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer.
    Schorge JO, Mahoney NM, Miller DS, Coleman RL, Muller CY, Euhus DM, Tomlinson GE.
    Gynecol Oncol; 2001 Nov 15; 83(2):383-7. PubMed ID: 11606101
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.